Skip to main content
. 2016 Jun 3;7(26):40657–40673. doi: 10.18632/oncotarget.9813

Figure 3. miR-558 recruits AGO2 to facilitate the translation of HIF-2α in NB cells.

Figure 3

A. RNA pull-down assay showing the binding of HIF-2α 5′-UTR to AGO1, AGO2, AGO3, or AGO4 in IMR32 cells transfected with anti-NC (100 nmol/L) or anti-miR-558 (100 nmol/L) inhibitors. B. RIP and real-time qRT-PCR assays indicating the binding of HIF-2α 5′-UTR to AGO1, AGO2, AGO3, or AGO4 in SH-SY5Y cells stably transfected with empty vector (mock) or miR-558 precursor. C. western blot assay showing the expression of AGO2 and HIF-2α in NB cells stably transfected with mock or miR-558 precursor, and those co-transfected with sh-Scb or sh-AGO2. D. dual-luciferase assay indicating the activity of HIF-2α 5′-UTR luciferase reporter in SH-SY5Y and SK-N-SH cells stably transfected with mock or miR-558 precursor, and those co-transfected with sh-Scb or sh-AGO2. E. sucrose gradient sedimentation assay showing the distribution of HIF-2α transcripts to the polysome fractions in NB cells transfected with sh-Scb or sh-AGO2. * P<0.01 vs. IgG, mock+sh-Scb, or sh-Scb.